Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • Authors & Reviewers
    • Overview for Authors
    • Preparing manuscripts
    • Submission Checklist
    • Publication Fees
    • Forms
    • Editorial Policies
    • Editorial Process
    • Patient-Oriented Research
    • Submit a manuscript
    • Manuscript Progress
    • Submit a response
    • Information for Reviewers
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ Open
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN
CMAJ Open

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • Authors & Reviewers
    • Overview for Authors
    • Preparing manuscripts
    • Submission Checklist
    • Publication Fees
    • Forms
    • Editorial Policies
    • Editorial Process
    • Patient-Oriented Research
    • Submit a manuscript
    • Manuscript Progress
    • Submit a response
    • Information for Reviewers
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow CMAJ Open on Twitter
Research

Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study

Lisa-Ann Fraser, Jordan M. Albaum, Mina Tadrous, Andrea M. Burden, Salimah Z. Shariff and Suzanne M. Cadarette
March 25, 2015 3 (1) E91-E96; DOI: https://doi.org/10.9778/cmajo.2014-0090
Lisa-Ann Fraser
1Department of Medicine, University of Western Ontario, London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordan M. Albaum
2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mina Tadrous
2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea M. Burden
2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salimah Z. Shariff
3Institute for Clinical and Evaluative Sciences (ICES), London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne M. Cadarette
2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ont.
3Institute for Clinical and Evaluative Sciences (ICES), London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1:

    Number of brand-name and generic bisphosphonate prescriptions dispensed from pharmacies to patients aged 65 years and older who lived in the community. ALN = alendronate, vitD3 = vitamin D3, RSD = risedronate, DR = delayed release, Ca = calcium.

  • Figure 2:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2:

    Number of brand-name and generic bisphosphonate prescriptions dispensed from pharmacies to patients aged 65 years and older who lived in a long-term care facility. ALN = alendronate, vitD3 = vitamin D3, RSD = risedronate, DR = delayed release, Ca = calcium.

Tables

  • Figures
    • View popup
    Table 1: Dates when the generic bisphosphonates were first dispensed in Ontario by the ODB formulary
    Generic bisphosphonateDate
    Daily alendronateSept. 2003
    Weekly alendronateJuly 2005
    Daily risedronateApr. 2010
    Weekly risedronateApr. 2010
    Monthly risedronateJune 2012
    Weekly alendronate + vitamin DJan. 2014

    Note: ODB = Ontario Drug Benefit.

      • View popup
      Table 2: Percentage of generic oral bisphosphonates of the total dispensed by ODB in the 3 months following formulary availability
      Generic bisphosphonate Percentage of total drugs dispensed to patients in the communityPercentage of total drugs dispensed to patients in long-term care facilities
      1st mo2nd mo3rd mo1st mo2nd mo3rd mo
      Daily alendronate596781488388
      Weekly alendronate438895479398
      Daily risedronate15738573783
      Weekly risedronate189196189699
      Monthly risedronate138693 68495
      Weekly alendronate + vitamin D518090649599

      Note: ODB = Ontario Drug Benefit.

      PreviousNext
      Back to top

      In this issue

      CMAJ Open: 3 (1)
      Vol. 3, Issue 1
      13 Jan 2015
      • Table of Contents
      • Index by author

      Article tools

      Respond to this article
      Print
      Download PDF
      Article Alerts
      To sign up for email alerts or to access your current email alerts, enter your email address below:
      Email Article

      Thank you for your interest in spreading the word on CMAJ Open.

      NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

      Enter multiple addresses on separate lines or separate them with commas.
      Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study
      (Your Name) has sent you a message from CMAJ Open
      (Your Name) thought you would like to see the CMAJ Open web site.
      CAPTCHA
      This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
      Citation Tools
      Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study
      Lisa-Ann Fraser, Jordan M. Albaum, Mina Tadrous, Andrea M. Burden, Salimah Z. Shariff, Suzanne M. Cadarette
      Jan 2015, 3 (1) E91-E96; DOI: 10.9778/cmajo.2014-0090

      Citation Manager Formats

      • BibTeX
      • Bookends
      • EasyBib
      • EndNote (tagged)
      • EndNote 8 (xml)
      • Medlars
      • Mendeley
      • Papers
      • RefWorks Tagged
      • Ref Manager
      • RIS
      • Zotero
      Share
      Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study
      Lisa-Ann Fraser, Jordan M. Albaum, Mina Tadrous, Andrea M. Burden, Salimah Z. Shariff, Suzanne M. Cadarette
      Jan 2015, 3 (1) E91-E96; DOI: 10.9778/cmajo.2014-0090
      Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
      • Tweet Widget
      • Facebook Like

      Related Articles

      • PubMed
      • Google Scholar

      Cited By...

      • No citing articles found.
      • Google Scholar

      Similar Articles

      Collections

      • Clinical
        • Rheumatology
          • Osteoporosis
        • Drugs
          • Other drug use
        • Geriatric Medicine
          • Other geriatric medicine
      • Nonclinical
        • Health Policy
          • Other health policy

      Content

      • Current issue
      • Past issues
      • Collections
      • Alerts
      • RSS

      Authors & Reviewers

      • Overview for Authors
      • Preparing manuscripts
      • Manuscript Submission Checklist
      • Publication Fees
      • Forms
      • Editorial Policies
      • Editorial Process
      • Patient-Oriented Research
      • Submit a manuscript
      • Manuscript Progress
      • Submit a response
      • Information for Reviewers

      About

      • General Information
      • Staff
      • Editorial Board
      • Contact Us
      • Advertising
      • Media
      • Reprints
      • Copyright and Permissions
      • Accessibility
      • CMA Civility Standards
      CMAJ Group

      Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 2291-0026

      All editorial matter in CMAJ OPEN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

      To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].

      View CMA's Accessibility policy.

       

      Powered by HighWire